266 related articles for article (PubMed ID: 10603193)
21. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
Ueda J; Iwata T; Ono M; Takahashi M
Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
[TBL] [Abstract][Full Text] [Related]
22. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
23. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
Dejmek A; Hjerpe A
Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
[TBL] [Abstract][Full Text] [Related]
24. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
Hecht JL; Pinkus JL; Pinkus GS
Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
[TBL] [Abstract][Full Text] [Related]
26. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
[TBL] [Abstract][Full Text] [Related]
27. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids.
Afify AM; Al-Khafaji BM; Paulino AF; Davila RM
Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):178-82. PubMed ID: 12051638
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
31. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
[TBL] [Abstract][Full Text] [Related]
32. An Updated Contextual Approach to Mesothelial Proliferations in Pleural Effusion Cytology Leveraging Morphology, Ancillary Studies, and Novel Biomarkers.
Miller LJ; Holmes IM; Lew M
Arch Pathol Lab Med; 2024 Apr; 148(4):409-418. PubMed ID: 37622452
[TBL] [Abstract][Full Text] [Related]
33. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology.
Fetsch PA; Abati A; Hijazi YM
Cancer; 1998 Apr; 84(2):101-8. PubMed ID: 9570213
[TBL] [Abstract][Full Text] [Related]
34. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
Ruitenbeek T; Gouw AS; Poppema S
Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629
[TBL] [Abstract][Full Text] [Related]
35. Ultrastructure of pleural mesothelioma and pulmonary adenocarcinoma in malignant effusions as compared with reactive mesothelial cells.
Sakuma N; Kamei T; Ishihara T
Acta Cytol; 1999; 43(5):777-85. PubMed ID: 10518130
[TBL] [Abstract][Full Text] [Related]
36. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
Jo VY; Cibas ES; Pinkus GS
Cancer Cytopathol; 2014 Apr; 122(4):299-306. PubMed ID: 24421209
[TBL] [Abstract][Full Text] [Related]
37. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
Maguire B; Whitaker D; Carrello S; Spagnolo D
Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591
[TBL] [Abstract][Full Text] [Related]
39. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]